Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Enlicitide decanoate by Merck for Atherosclerosis: Likelihood of Approval
Enlicitide decanoate is under clinical development by Merck and currently in Phase III for Atherosclerosis. According to GlobalData, Phase III...
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's Enlicitide decanoate?
Enlicitide decanoate is a peptide commercialized by Merck, with a leading Phase III program in Hypercholesterolemia. According to Globaldata, it...